Replies to post #117917 on Biotech Values

[gdollasign]

Good points all mcbio. MNTA is less of a risk asset but I think the potential for AMRN is beyond massive. Thanks for the feedback.

[iandy]

I see AMRN as a great bio run-up play.
Odds are it will go to at least 10 in anticipation of ANCHOR results.

Andy

[JJM760]

I have AMRN in a basket with stocks like ZIOP, CRIS, NEOP, etc. and yes, my beloved ARIA. I would call that basket "ASCO run-ups/spec bio's" (not all are oncology companies). They certainly higher beta, but also higher potential alpha. I spread them out to help minimize the risk if 1 or 2 fail. All of these have had substantial increases in PPS lately. Abstracts are due 5/18, so I will make decisions on trimming down my positions by then or so.

After reading so much about it here, I happen to really like MNTA as well. However I believe MNTA belongs in another category. Much less beta than the others mentioned, IMO.

That's my 2 cents.

Regards, Joe